Nanjing Kangyi Biomedical Center LP has disclosed compounds with dipyrrolopyridine structure acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of cancer, asthma, atopic dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and inflammatory bowel disease, among others.